Active Ingredient History
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular mooth muscle cells than on cardiac muscle cells. Amlodipine is indicated for the treatment of hypertension and coronary artery disease. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adrenal Gland Neoplasms (Phase 2)
Albuminuria (Phase 4)
Alzheimer Disease (Phase 2/Phase 3)
Angina Pectoris (Phase 4)
Anxiety (Phase 4)
Aortic Aneurysm, Abdominal (Phase 2)
Aortic Valve Insufficiency (Phase 4)
Aortic Valve Stenosis (Phase 4)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
beta-Thalassemia (Phase 2/Phase 3)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 1)
Cardiovascular Diseases (Phase 4)
Carotid Stenosis (Phase 4)
Cerebral Hemorrhage (Phase 3)
Cerebral Small Vessel Diseases (Phase 3)
Cognition Disorders (Phase 2/Phase 3)
Cognitive Dysfunction (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Dementia, Vascular (Phase 3)
Depression (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Diabetic Retinopathy (Phase 3)
Drug Interactions (Phase 1)
Drug Misuse (Phase 4)
Dyslipidemias (Phase 4)
Dystonic Disorders (Phase 2)
Edema (Phase 2)
Endothelial Cells (Phase 2)
Erectile Dysfunction (Phase 3)
Essential Hypertension (Phase 4)
Fasting (Phase 1)
Fertilization in Vitro (Phase 2)
Healthy Volunteers (Phase 1)
Heart Disease Risk Factors (Phase 4)
Heart Diseases (Phase 4)
Heart Failure (Phase 3)
Heart Failure, Diastolic (Phase 4)
Heart Ventricles (Phase 4)
Hemorrhage (Phase 4)
Hepatitis C (Phase 1)
HIV (Phase 1)
HIV Infections (Phase 2)
Hyperaldosteronism (Phase 2)
Hypercholesterolemia (Phase 4)
Hyperhomocysteinemia (Phase 4)
Hyperlipidemias (Phase 4)
Hypertension ()
Hypertension, Pregnancy-Induced (Phase 4)
Hypertension, Renal (Phase 4)
Hypertension, Renovascular (Phase 3)
Hypertrophy, Left Ventricular (Phase 4)
Hypoxia (Phase 4)
Insulin Resistance (Phase 2)
Iron Overload (Phase 3)
Ischemic Stroke (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Lipid Metabolism Disorders (Phase 4)
Masked Hypertension (Phase 4)
Metabolic Syndrome (Phase 4)
Minerals (Phase 4)
Myocardial Infarction (Phase 3)
Myocardial Ischemia (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Obesity, Abdominal (Phase 2)
Pancreatitis (Phase 1/Phase 2)
Peripheral Arterial Disease (Phase 4)
Pharmacogenetics (Phase 4)
Pharmacokinetics (Phase 1)
Postural Balance (Phase 4)
Prehypertension (Phase 4)
Proteinuria (Phase 4)
Quality of Life (Phase 4)
Raynaud Disease (Phase 2/Phase 3)
Renal Artery Obstruction (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Renin-Angiotensin System (Phase 4)
Sclerosis (Phase 3)
Sleep Apnea, Obstructive (Phase 4)
Sleep Apnea Syndromes (Phase 4)
Stroke (Phase 4)
Thalassemia (Phase 3)
Therapeutic Equivalency (Phase 1)
Vascular Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
